{
    "nctId": "NCT05795335",
    "briefTitle": "CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer",
    "officialTitle": "Survival Outcomes, Adverse Events and Predictive Biomarkers for CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer, an Ambispective Single-center Cohort Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 172,
    "primaryOutcomeMeasure": "Progression-Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged \u226518 and older\n* Confirmed diagnosis of hormone receptor-positive breast cancer.\n* Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy.\n* Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease.\n* ECOG 0-2\n* Adequate organ function\n\nExclusion Criteria:\n\n* Subjects disable to swallow pills.\n* History of immunodeficiency disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}